Introduction to GLP-1 Agonists GLP-1 agonists have been pivotal in the pharmaceutical market for nearly two decades, beginning with the FDA approval of AstraZenecas Byetta in 2005
Metabolic syndrome with elevated liver enzymes : Patients presenting with multiple metabolic risk factors (central obesity, hypertension, dyslipidemia, impaired fasting glucose) and persistently elevated ALT/AST may benefit from the comprehensive metabolic improvements offered by GLP-1 therapy
Retatrutide is now being further evaluated in large-scale phase 3 clinical trials under the TRIUMPH program, which includes multiple studies assessing its effects in obesity, overweight with comorbidities, and type 2 diabetes
It's found in every cell in your body, where its most important job is to help turn food into energy
The abdomen is preferred because it has consistent subcutaneous fat depth and is easy to access